CanSino Biologics Inc. (FRA:CJH)

Germany flag Germany · Delayed Price · Currency is EUR
4.160
-0.020 (-0.48%)
Last updated: Dec 5, 2025, 9:59 AM CET
16.20%
Market Cap 1.48B
Revenue (ttm) 116.35M
Net Income (ttm) -17.00M
Shares Out n/a
EPS (ttm) -0.07
PE Ratio n/a
Forward PE 51.18
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 83
Open 4.160
Previous Close 4.180
Day's Range 4.160 - 4.160
52-Week Range 3.120 - 6.000
Beta n/a
RSI 32.41
Earnings Date Mar 25, 2026

About CanSino Biologics

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 1,105
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CJH
Full Company Profile

Financial Performance

In 2024, CanSino Biologics's revenue was 846.34 million, an increase of 137.01% compared to the previous year's 357.08 million. Losses were -378.88 million, -74.45% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.